Cosciens Biopharma (TSX:CSCI) LT-Debt-to-Total-Asset : 0.06 (As of Dec. 2024)

View and export this data going back to 1992. Start your Free Trial

What is Cosciens Biopharma LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Cosciens Biopharma's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.06.

Cosciens Biopharma's long-term debt to total assets ratio declined from Dec. 2023 (0.06) to Dec. 2024 (0.06). It may suggest that Cosciens Biopharma is progressively becoming less dependent on debt to grow their business.

Cosciens Biopharma LT-Debt-to-Total-Asset Historical Data

The historical data trend for Cosciens Biopharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosciens Biopharma LT-Debt-to-Total-Asset Chart

Cosciens Biopharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.09

0.08

0.06

Cosciens Biopharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.06	0.06	0.03	0.03	0.06

Cosciens Biopharma LT-Debt-to-Total-Asset Calculation

Cosciens Biopharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	2.905	/	49.964
	=	0.06

Cosciens Biopharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	2.905	/	49.964
	=	0.06

Cosciens Biopharma (TSX:CSCI) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Cosciens Biopharma LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Cosciens Biopharma's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Cosciens Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cosciens Biopharma Inc (TSX:CSCI) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

CSCI:USA ET8:Germany

Address

c/o Norton Rose Fulbright Canada LLP, 222 Bay Street, Suite 3000, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology.

Executives